SEC Form 424B3 filed by Cardio Diagnostics Holdings Inc.
$CDIO
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)
4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)
4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)
The final gapfill payment rate for both the Epi+Gen CHD™ and PrecisionCHD™ tests is higher at $854 compared to the preliminary gapfill payment rates of $350 for Epi+Gen CHD™ and $684.76 for PrecisionCHD™. Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), an AI-powered precision cardiovascular medicine company, today announced that the Centers for Medicare and Medicaid Services (CMS) has issued a final gapfill payment rate of $854 for both the Epi+Gen CHD™ and PrecisionCHD™ tests. This finalized rate represents an increase from the preliminary gapfill payment rates of $350 for Epi+Gen CHD™ and $684.76 for PrecisionCHD™. Obtaining the final rate represents a positive development and will be e
Ischemia with No Obstructive Coronary Arteries (INOCA) and Myocardial Infarction with No Obstructive Coronary Arteries (MINOCA) are two underdiagnosed, potentially fatal forms of heart disease that standard diagnostic testing routinely fails to detect Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), an AI-powered Precision Cardiovascular Medicine company, today announced that the Company will be presenting new data at the American Heart Association (AHA) Scientific Sessions demonstrating that the epigenetic biomarkers of the Company's PrecisionCHD test are able to detect Ischemia with No Obstructive Coronary Arteries (INOCA) and Myocardial Infarction with No Obstructive Coronary Arteries (
A customized program for YMCA of East Tennessee members will include educational series "Wisdom Wednesdays," and access to Cardio Diagnostics' AI-powered cardiovascular testing at discounted rates from home or during the Heart Health Fair Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), an AI-powered precision cardiovascular medicine company, today announced that the Company is partnering with YMCA of East Tennessee to launch a customized program exclusively for its members. Through this program, YMCA members will learn how to take proactive steps to prevent and detect heart disease early while gaining access to Epi+Gen CHD™ and PrecisionCHD™ clinical tests from Cardio Diagnostics at a sp
4/A - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)
4/A - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)
4/A - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)
10-Q - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)
8-K - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)
424B3 - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)
Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), an AI-driven precision cardiovascular medicine company, today announced the appointment of Dr. Vimal Ramjee, MD FACC CCMS, as a Strategic Advisor. Dr. Ramjee is a cardiologist and a health innovation leader, serving as the National Co-Chair of Cardiology and Innovation at CommonSpirit Health Enterprise and is also a member of the American Heart Association Board of Directors. The appointment of Dr. Ramjee as a Strategic Advisor to Cardio Diagnostics is a significant development to the Company's continued growth and market expansion. He brings a wealth of experience and proven track record in clinical practice, innovation and research, makin
Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), an AI-driven precision cardiovascular medicine company, today announced the appointment of Paul Burton, J.D., MBA to its Board of Directors as an Independent Director. Mr. Burton will Chair the Nominating and Corporate Governance Committee and will also serve as a member of the Audit Committee. Mr. Burton is the Managing Partner at 2Flo Ventures, an early-stage healthcare investor and startup studio focused on accelerating health equity. He is also the CEO of Akan Biosciences, a clinical-stage biotech company, and runs an advisory firm working closely with healthcare growth companies. Mr. Burton brings over 20 years of experience in medical
SC 13G/A - Cardio Diagnostics Holdings, Inc. (0001870144) (Subject)